Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 2, 2009, Pages 303-311

  Kanda, Shigeru ^a,b   Kanetake, Hiroshi ^a   Miyata, Yasuyoshi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

ERK; LY294002; PI3 kinase; PTEN; Resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; LIPOSOME; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BLADDER TUMOR; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; MITOSIS INDEX; MOLECULAR CLONING; PLASMID; PROSTATE TUMOR; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL DIVISION; CELL LINE, TUMOR; CHROMONES; CLONING, MOLECULAR; ENZYME INHIBITORS; HUMANS; LIPOSOMES; MALE; MITOTIC INDEX; MORPHOLINES; PLASMIDS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 65849180154     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-008-0465-4     Document Type: Article

References (28)

1. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K (2005) Targeting CK2 for cancer therapy. Anticancer Drug 16:1037-1043
2. Ali IU, Schriml LM, Dean M (1999) Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91:1922-1932
3. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T (2005) Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3β. J Biol Chem 280:35195-35202
4. Aveyard JS, Skilleter A, Habuchi T, Knowles MA (1999) Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80:904-908
5. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3 K deregulates transcription and translation. Nat Rev Cancer 5:921-929
6. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rozen N, Tsurutani J, Dennis PA, Miles GB, Arteaga CL (2003) Loss of PTEN/ MMAC1/TEP in EGF receptor- expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
7. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000
8. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3 K pathways as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
9. Downward J (2004) PI3-kinase, Akt and cell survival. Seminar Cell Develop Biol 15:177-182
10. Furnari FB, Huang HJ, Cavenee WK (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrests in glioma cells. Cancer Res 58:5002-5008
11. deGraVenried LA, Fulcher L, Friendrichs WE, Grunwals V, Ray RB, Hidalgo M (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15:1510-1516
12. Jiang B-H, Zheng JZ, Aoki M, Vogt PK (2000) Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97:1749-1753
13. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, Hahn SM, Gupta AK, Maity A (2007) Phosphatase and tensin homologue defficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelWnavir. Cancer Res 67:4467-4473
14. Kanda S, Lerner EC, Tsuda S, Shono T, Kanetake H, Smithgall TE (2000) The non- receptor protein-tyrosine kinase c-Fes is involved in FGF-2-induced chemotaxis of murine brain capillary endothelial cells. J Biol Chem 275:10105-10111
15. Kanda S, Miyata Y, Mochizuki Y, Matsuyama T, Kanetake H (2005) Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 65:6820-6827
16. Kanda S, Miyata Y, Kanetake H (2006a) Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059. Biochem Biophys Res Commun 345:1481-1486
17. Kanda S, Miyata Y, Kanetake H, Smithgall TE (2006b) Fibroblast growth factor-2 induces the activation of Src through Fes, which regulates focal adhesion disassembly. Exp Cell Res 312:3015-3022
18. Lebrin F, Chambaz EM, Biabchini L (2001) A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit α. Oncogene 20:2010-2022
19. Lee S, Choi EJ, Jin C, Kim DH (2005) Activation of PI3 K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97:26-34
20. Leslie NR, Downes CP (2004) PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382:1-11
21. Li DM, Sun H (1998) PTEN/MMAC1/TEP1 supresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95:15406-15411
22. Lim K-H, Counter CM (2005) Reduction in the requirement of oncogenic Ras signaling to activation of PI3 K/AKT pathway during tumor maintenance. Cancer Cell 8:381-392
23. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahim AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
24. Neshat MS, MellinghoV IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-Defficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314-10319
25. Stein RC (2001) Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8:237-248
26. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman H (2000) MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19:5406-5412
27. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297:63-64
28. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W (2003) Preferential killing of PTEN-null myelomas by PI3 K inhibitors through Akt pathway. Oncogene 22:6289-6295